Treating depression in the era of precision medicine: Challenges and perspectives

Michael Musker, Ma Li Wong

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    1 Citation (Scopus)


    We are at the dawn of a new era of treatment for major depressive disorder involving precision medicine. Research is using big data, genome-wide association studies, and pharmacogenomics to create a combinatorial biological and environmental model of depression. Biomarkers have already been used to indicate causative pathways and the effectiveness of treatment responses in other areas of medicine. As technology advances, psychiatric practice will be able to use new tools and technology to assist with diagnosis and drug treatment options. The complex interaction of the inherited genome, epigenetic responses, pharmacokinetics, and environmental factors combine to produce endophenotypic outcomes that are predictable. The prevalence and cost burden of depression are so great that improved diagnostic tools are needed. The role of pharmacogenomics and related sciences pharmacokinetics and pharmacodynamics are discussed.

    Original languageEnglish
    Title of host publicationNeurobiology of Depression
    Subtitle of host publicationRoad to Novel Therapeutics
    EditorsJoao Quevedo, Andre F. Carvalho, Carlos A. Zarate
    Place of PublicationUnited Kingdom
    Number of pages11
    ISBN (Electronic)9780128133330
    ISBN (Print)9780128133347
    Publication statusPublished - 1 Jan 2019


    • Biomarkers
    • Cytokines
    • Genome wide association studies
    • Genomics
    • Major depressive disorder
    • Pharmacodynamics
    • Pharmacogenomics
    • Precision medicine


    Dive into the research topics of 'Treating depression in the era of precision medicine: Challenges and perspectives'. Together they form a unique fingerprint.

    Cite this